~~<i id='3F637C12DE'><strike id='3F637C12DE'><tt id='3F637C12DE'><pre id='3F637C12DE'></pre></tt></strike></i>~~

Home» comprehensive» entertainment

entertainment

author：Wikipedia 2025-09-29 16:37:28 Page View：71

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： iTeos Therapeutics debuts first data on TIGIT
Next article： At least 13 dead in Texas as scorching temps continue

knowledge

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

KatiePalmer,STAT(left)moderatingtheDoctorvs.ChatGPTsessionduringthe2023STATSummit.STATGenerativeAIto

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

STAT Summit: The economic case for universal basic health care

MITeconomistAmyFinkelsteinchatswithSTAT'sBobHermanatthe2023STATSummit.STATFixingtheU.S.healthcaresys

WSS

entertainment

entertainment

explore

knowledge

STAT Summit: The economic case for universal basic health care